Cost-Effectiveness of Blinatumomab in Pediatric Patients with High-Risk First-Relapse B-Cell Precursor Acute Lymphoblastic Leukemia in France

Megane Caillon (), Benoit Brethon, Chrissy Beurden-Tan, Romain Supiot, Antoine Mezo, Jean-Vannak Chauny, Istvan Majer and Arnaud Petit
Additional contact information
Megane Caillon: Amgen (France) SAS, Arcs de Seine
Benoit Brethon: Robert-Debré Hospital, AP-HP
Chrissy Beurden-Tan: Amgen (Europe) GmbH
Romain Supiot: Putnam PHMR
Antoine Mezo: Amgen (France) SAS, Arcs de Seine
Jean-Vannak Chauny: Amgen (France) SAS, Arcs de Seine
Istvan Majer: Amgen (Europe) GmbH
Arnaud Petit: Armand Trousseau Hospital, AP-HP, Sorbonne University

PharmacoEconomics - Open, 2023, vol. 7, issue 4, No 11, 639-653

Abstract: Abstract Background Based on the results of the phase III randomized 20120215 trial, the European Medicines Agency granted the approval of blinatumomab for the treatment of pediatric patients with high-risk first-relapsed Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (ALL). In France, blinatumomab received reimbursement for this indication in May 2022. This analysis assessed the cost effectiveness of blinatumomab compared with high-risk consolidation chemotherapy (HC3) in this indication from a French healthcare and societal perspective. Methods A partitioned survival model with three health states (event-free, post-event and death) was developed to estimate life-years (LYs), quality-adjusted life-years (QALYs) and costs over a lifetime horizon. Patients who were alive after 5 years were considered to be cured. An excess mortality rate was applied to capture the late effects of cancer therapy. Utility values were based on the TOWER trial using French tariffs, and cost input data were identified from French national public health sources. The model was validated by clinical experts. Results Treatment with blinatumomab over HC3 was estimated to provide gains of 8.39 LYs and 7.16 QALYs. Total healthcare costs for blinatumomab and HC3 were estimated to be €154,326 and €102,028, respectively, resulting in an increment of €52,298. The incremental cost-effectiveness ratio was estimated to be €7308 per QALY gained from a healthcare perspective. Results were robust to sensitivity analyses, including analysis from the societal perspective. Conclusions Blinatumomab administered as part of consolidation therapy in pediatric patients with high-risk first-relapsed ALL is cost effective compared with HC3 from the French healthcare and societal perspective.

Keywords: Blinatumomab; France; Acute lymphoblastic leukemia; Pediatric; Cost-effectiveness; Economic evaluation; Societal perspective (search for similar items in EconPapers)
Date: 2023
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s41669-023-00411-4 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:pharmo:v:7:y:2023:i:4:d:10.1007_s41669-023-00411-4

Ordering information: This journal article can be ordered from
http://www.springer.com/adis/journal/41669

DOI: 10.1007/s41669-023-00411-4

Access Statistics for this article

PharmacoEconomics - Open is currently edited by Timothy Wrightson and Christopher Carswell

More articles in PharmacoEconomics - Open from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().